Abstract:The Kirsten rat sarcoma viral (KRAS) oncogene is the most frequently mutated isoform of RAS, associated with 85 % of RAS-driven cancers. KRAS functions as a signaling hub, participating in various cellular signaling pathways and regulating a wide range of important activities, including cell proliferation, differentiation, growth, metabolism, and migration. Despite being the most frequently altered oncogenic protein in solid tumors, over the past four decades, KRAS has historically been considered "undruggable" owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design and development have culminated in the development of selective inhibitors for KRAS mutants. Recent developments have led to the successful targeting of the KRASG12C mutant through covalent inhibitors that exploit the unique cysteine residue introduced by the mutation at 12th position. These inhibitors bind covalently to C12, locking KRAS in its inactive GDP-bound state and preventing downstream signaling. Some of these inhibitors have shown encouraging results in KRASG12C mutant cancer patients but suffer from drug resistance, toxicity, and low therapeutic efficacy. Recently, there have been great advancements in the discovery of drugs that directly target the switch I (S-I), switch-II (S-II) and S-I/II interface sites of KRAS mutant proteins. These include KRASG12C inhibitors like AMG510 (Sotorasib) and MRTX849 (Adagrasib), which have got FDA approval for non-small cell lung cancer harboring the KRASG12C mutation. There is no approved drug for cancers harboring other KRAS mutations, although efforts have expanded to target other KRAS mutations and the Switch I/II interface, aiming to disrupt KRAS-driven oncogenic signaling. Structure-activity relationship (SAR) studies have been instrumental in optimizing the binding affinity, selectivity, and pharmacokinetic properties of these inhibitors, leading to the development of promising therapeutic agents like Sotorasib and Adagrasib. This review provides an overview of the KRAS pathway, KRAS binding sites, strategies for direct and indirect inhibition using small molecules, and SAR based on the co-crystal structures of inhibitors with KRAS mutants which is expected to offer new hope for patients with KRAS-driven cancers through the development of new KRAS-targeted drugs.

KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms

Targeting KRAS in cancer

Targeting cancer with small-molecule pan-KRAS degraders

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Insights into Direct KRAS Inhibition Strategies for Cancer Treatment

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

KRAS mutation: from undruggable to druggable in cancer

Targeting cancer with small molecule pan-KRAS degraders

Drug Discovery by Targeting Mutant KRAS.

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

A Pan-Kras Degrader for the Treatment of KRAS-mutant Cancers.

Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors

Drugging KRAS: current perspectives and state-of-art review

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies